Hyperthermic isolated limb perfusion in the management of extremity sarcoma

Current Opinion in Oncology

Volumn 15, Issue 4, 2003, Pages 300-303

  Hoekstra, H J ^a   Van Ginkel, R J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytokine; Limb salvage; Perfusion; Sarcoma; Tumor necrosis factor

Indexed keywords

CISPLATIN; DACTINOMYCIN; DOXORUBICIN; MELPHALAN; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; LIMB SALVAGE; LOW DRUG DOSE; MORBIDITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELPHALAN; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0043240364     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200307000-00004     Document Type: Review

References (12)

1. Ham SJ, van der Graaf WTA, Pras E, et al: Soft tissue sarcoma of the extremities: a multimodality diagnostic and therapeutic approach. Cancer Treat Rev 1998, 24:373-391.
2. Lienard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
3. Lejeune FJ, Kroon BBR, Di Filippo F, et al: Isolated limb perfusion: the European experience. Surg Clin North Am 2001, 10:807-821.
4. Eggermont AM, Schraffordt Koops H, Lienard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
5. Daryanani D, Komdeur R, Ter Veen J, et al: Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001, 8:566-572.
6. Van Ginkel RJ, Limburg PC, Piers DA, et al: Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 2002, 9:355-363.
7. Van Etten B, van Geel AN, de Wilt JH, et al: Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2002, 10:32-37.
8. Lans TE, de Wilt JH, van Geel AN, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangio-sarcoma. Ann Surg Oncol 2002, 9:1004-1009.
9. Lans TE, ten Hagen TL, van Horssen R, et al: Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. Ann Surg Oncol 2002, 9:812-819.
10. Stein U, Jurchott K, Schlafke M, et al: Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma. J Clin Oncol 2002, 20:3282-3292.
11. Komdeur R, Plaat BE, Hoekstra HJ, et al: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 2001, 91:1940-1948.
12. Seynhave AL, de Wilt JH, van Tiel ST, et al: Isolated limb perfusion with actinomycin-D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer 2002, 86:1174-1179.